|
|||||
|
|
Author's response: ‘Transition considerations for extended half‐life factor products’ |
|
| Authors: | S. E. Croteau E. J. Neufeld |
| Affiliation: | Dana Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA |
| Abstract: | |
| Keywords: | |